Published in Leukemia on December 24, 2013
An overview on CALR and CSF3R mutations and a proposal for revision of WHO diagnostic criteria for myeloproliferative neoplasms. Leukemia (2014) 2.28
Distinct clinical characteristics of myeloproliferative neoplasms with calreticulin mutations. Haematologica (2014) 1.14
Differential association of calreticulin type 1 and type 2 mutations with myelofibrosis and essential thrombocytemia: relevance for disease evolution. Leukemia (2014) 1.12
Frequent CALR exon 9 alterations in JAK2 V617F-mutated essential thrombocythemia detected by high-resolution melting analysis. Blood Cancer J (2015) 0.89
Stathmin 1 inhibition amplifies ruxolitinib-induced apoptosis in JAK2V617F cells. Oncotarget (2015) 0.89
High resolution melting analysis: a rapid and accurate method to detect CALR mutations. PLoS One (2014) 0.87
JAK2, CALR, and MPL mutation spectrum in Japanese patients with myeloproliferative neoplasms. Haematologica (2014) 0.85
Somatic mutations of calreticulin in a Brazilian cohort of patients with myeloproliferative neoplasms. Rev Bras Hematol Hemoter (2015) 0.79
Calreticulin mutations in myeloproliferative neoplasms. Rambam Maimonides Med J (2014) 0.77
Effect of conditioning regimens on graft failure in myelofibrosis: a retrospective analysis. Bone Marrow Transplant (2015) 0.76
Coexistence of JAK2 and CALR mutations and their clinical implications in patients with essential thrombocythemia. Oncotarget (2016) 0.75
Screening PCR Versus Sanger Sequencing: Detection of CALR Mutations in Patients With Thrombocytosis. Ann Lab Med (2016) 0.75
Clinical relevance between CALR mutation and myeloproliferative neoplasms. Stem Cell Investig (2015) 0.75
Coexisting JAK2V617F and CALR Exon 9 Mutation in Essential Thrombocythemia. Indian J Hematol Blood Transfus (2016) 0.75
Clinical Manifestation of Calreticulin Gene Mutations in Essential Thrombocythemia without Janus Kinase 2 and MPL Mutations: A Chinese Cohort Clinical Study. Chin Med J (Engl) (2016) 0.75
Somatic mutations of calreticulin in myeloproliferative neoplasms. N Engl J Med (2013) 9.65
Somatic CALR mutations in myeloproliferative neoplasms with nonmutated JAK2. N Engl J Med (2013) 8.89
Calreticulin: one protein, one gene, many functions. Biochem J (1999) 3.16
Calreticulin: non-endoplasmic reticulum functions in physiology and disease. FASEB J (2009) 2.48
Guideline for investigation and management of adults and children presenting with a thrombocytosis. Br J Haematol (2010) 2.32
Enhanced catalysis of ribonuclease B folding by the interaction of calnexin or calreticulin with ERp57. J Biol Chem (1998) 2.27
Expression of calreticulin in Escherichia coli and identification of its Ca2+ binding domains. J Biol Chem (1991) 1.89
The anti-adhesive activity of thrombospondin is mediated by the N-terminal domain of cell surface calreticulin. J Biol Chem (2002) 1.23
ERp57 modulates STAT3 signaling from the lumen of the endoplasmic reticulum. J Biol Chem (2009) 1.16
Calreticulin enhances porcine wound repair by diverse biological effects. Am J Pathol (2008) 1.10
Calreticulin, an antithrombotic agent which binds to vitamin K-dependent coagulation factors, stimulates endothelial nitric oxide production, and limits thrombosis in canine coronary arteries. J Biol Chem (1995) 1.01
Consistent up-regulation of Stat3 Independently of Jak2 mutations in a new murine model of essential thrombocythemia. Cancer Res (2009) 0.98
Physical and functional interaction between cell-surface calreticulin and the collagen receptors integrin alpha2beta1 and glycoprotein VI in human platelets. Thromb Haemost (2002) 0.96
Crucial role for endoplasmic reticulum stress during megakaryocyte maturation. Arterioscler Thromb Vasc Biol (2013) 0.87